NEW
YORK, Oct. 9, 2024 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the
"Company"), a commercial-stage, cancer prevention medical
diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM),
today announced that it will participate in the 2024 Maxim
Healthcare Virtual Summit.
Event Details:
- Date: Tuesday, October 15,
2024
- Time: 11:30 AM Eastern Time
- Format: Fireside Chat with Dennis
McGrath, Lucid's Chief Financial Officer
- Venue: Virtual
For more information about the 2024 Maxim Healthcare Virtual
Summit and to attend Lucid's fireside chat, please
visit https://m-vest.com/events/healthcare-10152024.
A recording of the fireside chat will be made available on the
investor relations section of the Company's website at
ir.luciddx.com following the conclusion of the conference.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage, cancer prevention medical diagnostics company and
subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the
millions of patients with gastroesophageal reflux disease (GERD),
also known as chronic heartburn, who are at risk of developing
esophageal precancer and cancer. Lucid's EsoGuard®
Esophageal DNA Test, performed on samples collected in a brief,
noninvasive office procedure with its EsoCheck®
Esophageal Cell Collection Device, represent the first and only
commercially available tools designed with the goal of preventing
cancer and cancer deaths through widespread, early detection of
esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com
and for more information about its parent company PAVmed, please
visit www.pavmed.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-the-2024-maxim-healthcare-virtual-summit-302271379.html
SOURCE Lucid Diagnostics
